Markets:

Overview

News

Currencies

International

Treasuries

Oncolytics Biotech Inc. - Common Shares (NQ:ONCY)

0.8556 +0.0456 (+5.63%)

Streaming Delayed Price Updated: 2:59 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Oncolytics Biotech Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >

Biotech Sector Gaining Wins Against Pancreatic Cancer with Early Detection and New Therapies

November 14, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –November 14, 2022 – USA News Group – English actor, comedian and Monty Python alumnus Eric Idle credits early detection for his...

Via FinancialNewsMedia

Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer

November 10, 2022

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END

Via FinancialNewsMedia

Earnings Scheduled For August 11, 2022 ↗

August 11, 2022

Companies Reporting Before The Bell • Magic Software (NASDAQ:MGIC) is projected to report quarterly earnings at $0.27 per share on revenue of $131.70 million.

Via Benzinga

Oncolytics Biotech® Presents Updated Clinical Data at SITC Annual Meeting Showing a 69% Objective Response Rate and Confirmed Complete Response in GOBLET Study’s Pancreatic Cancer Cohort

November 10, 2022

One complete response (CR) and eight partial responses (PR) achieved in thirteen evaluable patients 69% objective response rate (ORR) is nearly three times greater than the average ORR of ~25% reported...

Via FinancialNewsMedia

Why Huadi International Group Shares Dipped Around 91%; Here Are 79 Biggest Movers From Yesterday ↗

November 08, 2022

Gainers

Via Benzinga

Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday ↗

November 09, 2022

Gainers Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.

Via Benzinga

Recap: Oncolytics Biotech Q3 Earnings ↗

November 07, 2022

Oncolytics Biotech (NASDAQ:ONCY) reported its Q3 earnings results on Monday, November 7, 2022 at 08:03 AM. Here's what investors need to know about the announcement.

Via Benzinga

Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies

November 07, 2022

Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and...

Via FinancialNewsMedia

Oncolytics Biotech® Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 37th Annual Meeting

October 05, 2022

Interim results from the phase 1/2 GOBLET study’s pancreatic cancer cohort to be presented in a poster on November 11th and discussed during a key opinion leader webinar on November 14th at 10 a.m. ET...

Via FinancialNewsMedia

Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2022 ↗

October 06, 2022

Upgrades

Via Benzinga

Oncolytics Reports Partnering With Biopharma Industry Leaders To Fast-Track Immunotherapy Treatment ↗

June 02, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

R&D Efforts to Improve Optimal Treatments for Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Progressing

October 05, 2022

Palm Beach, FL – October 5, 2022 – FinancialNewsMedia.com News Commentary – Advanced pancreatic ductal adenocarcinoma (PDAC) remains a significant cause of mortality accounting for up to 4% of all...

Via FinancialNewsMedia

Topics Death

A Preview Of Oncolytics Biotech's Earnings ↗

May 04, 2022

Oncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-05-05. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Oncolytics Biotech® and SOLTI Present New Clinical Biomarker Data Demonstrating Pelareorep’s Potential to Improve the Prognosis of Breast Cancer Patients at the ESMO Breast Cancer Meeting

May 04, 2022

Pelareorep treatment resulted in a favorable Risk of Recurrence Score (ROR-S) in 100% of evaluable patients compared to 55% at baseline in a window-of-opportunity study Statistically significant...

Via FinancialNewsMedia

Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027

June 28, 2022

Palm Beach, FL – June 28, 2022 – FinancialNewsMedia.com News Commentary – Pancreatic cancer therapeutics and diagnostics involve medical procedures used to diagnose pancreatic cancer and subsequent...

Via FinancialNewsMedia

Oncolytics Expected To Announce Progress On New Glioblastoma Treatment This Spring ↗

March 15, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Recap: Oncolytics Biotech Q4 Earnings ↗

March 03, 2022

Oncolytics Biotech (NASDAQ:ONCY) reported its Q4 earnings results on Thursday, March 3, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings...

Via Benzinga

HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients

May 04, 2022

Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years...

Via FinancialNewsMedia

The Daily Biotech Pulse: NuCana Shelves Biliary Tract Cancer Study, Tricida Data Readout Pushed Back Due to Ukrainian Crisis, Synlogic Names New CFO ↗

March 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus NuCana Discontinues Biliary Tract Cancer Study Following Futility Analysis...

Via Benzinga

Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing

April 14, 2022

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically...

Via FinancialNewsMedia

Preview: Oncolytics Biotech's Earnings ↗

March 02, 2022

Oncolytics Biotech (NASDAQ:ONCY) is set to give its latest quarterly earnings report on Thursday, 2022-03-03. Here's what investors need to know before the announcement. Analysts...

Via Benzinga

The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗

February 27, 2022

Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first...

Via Benzinga

Optimism Builds for Promising Developments & New Drug Therapies Targeting Treatments for Breast Cancer

March 24, 2022

Palm Beach, FL – March 24, 2022 – FinancialNewsMedia.com News Commentary – The status of breast cancer as one of the most commonly occurring cancers in the world is expected to be a key driving factor...

Via FinancialNewsMedia

This Biotech Company Reports Making Ground-Breaking Strides In Combating Solid Tumors ↗

February 23, 2022

Photo by National Cancer Institute on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing...

Via Benzinga

Oncolytics Reports Foothold In Chinese Pharmaceutical Market With Latest Breast Cancer Clinical Trials ↗

February 16, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Oncolytics...

Via Benzinga

Earnings Scheduled For March 3, 2022 ↗

March 03, 2022

Companies Reporting Before The Bell • Travelzoo (NASDAQ:TZOO) is expected to report quarterly earnings at $0.13 per share on revenue of $18.23 million. • Urban...

Via Benzinga

Oncolytics Announced Updates On Clinical Trials Of New Treatment For Triple-Negative Metastatic Breast Cancer ↗

February 10, 2022

Image provided by Pexels This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

Groundbreaking Clinical Trials Accelerating New Treatment Options for Pancreatic Cancer

February 02, 2022

Palm Beach, FL – February 2, 2022 – FinancialNewsMedia.com News Commentary – In the battle against pancreatic cancer, new and innovative clinical trials have become extremely critical. These trials...

Via FinancialNewsMedia

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Promising Results Continue to Develop Optimism in Fight Against Cancers

January 27, 2022

FN Media Group Presents USA News Group News Commentary Vancouver, BC –January 27, 2021 – USA News Group – There’s plenty of optimism surrounding the major medical breakthroughs targeting multiple types...

Via FinancialNewsMedia

< Previous 1 2 3 4 5 6 7 8 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.